Physician profile
Marybeth Parisi
NPI 1639158769
$4,036.55
in general payments reported to CMS, 2019-2025
33 companies · $679 in 2025
The $679 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $117 · 2021: $195 · 2022: $884 · 2023: $829 · 2024: $517 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.77 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $453.85 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $391.19 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $389.91 | 2022-2025 | Opzelura |
| Pfizer INC. | $379.89 | 2019-2025 | |
| Abbvie INC. | $339.53 | 2019-2025 | |
| Leo Pharma INC. | $301.44 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $195.38 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $189.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $150.47 | 2022-2025 | Sotyktu |
| Almirall LLC | $148.55 | 2019-2023 | Seysara |
| Genzyme Corporation | $146.23 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $139.23 | 2019-2025 | Dupixent |
| Biofrontera INC. | $124.40 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $80.86 | 2019-2020 | |
| Ucb, INC. | $60.37 | 2025 | Bimzelx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $58.34 | 2019 | |
| Galderma Laboratories, L.P. | $52.83 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $50.97 | 2023-2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.23 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.66 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Celgene Corporation | $36.71 | 2019 | |
| Kyowa Kirin, INC. | $30.15 | 2019-2023 | Poteligeo |
| Prugen, INC. Pharmaceuticals | $28.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.84 | 2025 | Cuvitru |
| Csl Behring | $26.56 | 2025 | Hizentra |
| Organon LLC | $20.56 | 2025 | |
| Dusa Pharmaceuticals, INC. | $20.33 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.54 | 2023 | Ycanth |
| Organogenesis INC. | $19.51 | 2024 | |
| Dermavant Sciences, INC. | $18.08 | 2024 | Vtama |
| Merck Sharp & Dohme LLC | $16.39 | 2019 | |
| Mission Pharmacal Company | $14.25 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.07 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marybeth Parisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.